Skip to main content

Table 3 Quality of Life measures

From: A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss

Variable Treatment Group
LLLT (N = 15) Lorcaserin (N = 14) Combination (N = 13a)
LASA ± SD
 Baseline 8.0 ± 0.9 7.7 ± 1.8 7.4 ± 1.1
 Week 12 8.6 ± 0.9 8.6 ± 0.8 8.2 ± 1.3
 Delta +0.6 ± 0.9b +0.9 ± 1.9 +0.8 ± 1.2b
CES-D ± SD
 Baseline 2.0 ± 3.6 4.1 ± 6.6 2.8 ± 3.3
 Week 12 3.3 ± 4.4 3.7 ± 4.3 3.4 ± 2.8
 Delta +1.3 ± 2.5 −0.4 ± 4.8 +0.6 ± 2.8
BAS ± SD
 Baseline 3.7 ± 0.6 3.7 ± 0.5 3.7 ± 0.7
 Week 12 3.6 ± 0.5 3.9 ± 0.7 3.8 ± 0.8
 Delta −0.1 ± 0.6 +0.3 ± 0.4b +0.1 ± 0.7
BASS ± SD
 Baseline 3.0 ± 0.4 3.0 ± 0.5 3.0 ± 0.4
 Week 12 3.1 ± 0.3 3.3 ± 0.5 3.0 ± 0.8
 Delta +0.1 ± 0.4 +0.3 ± 0.4b 0.0 ± 0.6
IWQOL - TOTAL ± SD
 Baseline 54.1 ± 12.1 50.9 ± 15.3 62.8 ± 22.4
 Week 12 47.9 ± 7.4 47.6 ± 15.6 54.9 ± 21.9
 Delta −6.1 ± 10.4 −3.3 ± 8.7 −8.0 ± 7.9c
  1. BAS Body Appreciation Scale, BASS Body Area Satisfaction Scale, CESD-R Center for Epidemiologic Studies Depression Scale Revised, IWQOL-Lite Impact of Weight on Quality of Life - Lite, LASA Linear Analogue Self-Assessment, SD Standard Deviation
  2. aOf the 15 subjects assigned to the combination group, 2 discontinued prior to week 12 and are not included in the analysis
  3. b P < 0.05 for paired t-test comparing week 12 versus baseline
  4. c P < 0.01 for paired t-test comparing week 12 versus baseline